Azelaic acid is one of skincare’s stranger contradictions. It’s used to treat acne and rosacea, regulate abnormal keratinisation and reduce inflammatory signalling. Then you apply it and your face starts tingling as if the ingredient has missed the brief.

The explanations arrive quickly. Your barrier is damaged. The percentage is too high. It’s exfoliating, purging or, most reassuringly, the sting means it must be working. Your face can sting and still tell you very little about which of those stories, if any, is true.

Stinging is a recognised effect of azelaic acid, and it can occur without evidence that the ingredient has damaged the barrier. A compromised barrier can make the experience stronger. The formulation changes how much azelaic acid becomes available to the skin. And recent work suggests that the molecule can amplify a sensory pathway in keratinocytes rather than behaving only as a low-pH irritant.

The sting is real. It isn’t a diagnosis.

The Leaflet Got There First

Azelaic acid’s reputation as a comparatively well-tolerated active can make the sensation feel like an odd exception. The product information is less surprised.

Across three US rosacea trials, the prescribing information for Finacea 15% gel recorded burning, stinging or tingling in 29% of participants using the gel. The events were mild in 16%, moderate in 9% and severe in 4%. The corresponding figure in the vehicle groups was 5%, so the active formulation clearly contributed. The UK product information also places application-site burning and pain among the gel’s very common effects.

Those numbers aren’t a forecast for your face. They belong to one 15% gel, used in people with rosacea under the conditions of those trials. A 10% cosmetic emulsion and a 20% cream haven’t inherited the same adverse-event rate because they share an ingredient name.

The figures do one modest job well. They remove the mystery. Stinging is common enough to be stated clearly in the paperwork; it doesn’t prove that you applied the product incorrectly, and it isn’t confined to skin with an obviously damaged barrier.

The Word ‘Acid’ Has Too Many Roles

Azelaic acid is a nine-carbon dicarboxylic acid. That describes its chemistry; it gives the molecule no automatic membership to the same functional category as glycolic acid or salicylic acid. Azelaic acid is neither an alpha-hydroxy acid nor a beta-hydroxy acid.

It can influence abnormal keratinisation, but its clinical action doesn’t depend on exfoliating the surface. A sting is therefore not evidence that dead cells are being removed, a purge has begun or the ingredient is working harder. I’ve seen the sensation described as azelaic acid clearing something out. There’s honestly no drain being unclogged.

Acidity can still affect how a topical feels. The proportion of ionised and non-ionised azelaic acid changes with pH, and a low-pH vehicle may be uncomfortable on reactive skin. But pH doesn’t act alone. Before the molecule can enter the skin, it has to dissolve, leave the product and remain available for transport. The tube is already part of the chemistry.

Nan Li and colleagues showed how counterintuitive that can become in 2012. In an in-vitro hairless-mouse-skin model, they compared experimental formulations at pH 3.9 and 4.9. The pH 4.9 formula produced roughly five times the flux of ionised azelaic acid measured with the pH 3.9 formula. Better solubilisation at the higher pH outweighed the usual permeability disadvantage of a charged molecule.

Two products with the same azelaic-acid concentration can therefore deliver the molecule differently because the vehicle changes solubility, release and contact with the skin.

The experiment didn’t measure stinging in people, and mouse skin mounted in a diffusion cell cannot tell you how a finished serum will feel. It demonstrated why the shortcut fails. Lower pH doesn’t automatically deliver more azelaic acid, and the percentage on the label doesn’t say how much will reach living tissue.

The Epidermis Has Joined the Conversation

The stratum corneum is often described as though everything underneath it waits passively for a chemical to find a nerve ending. The epidermis is more involved than that. Keratinocytes express sensory ion channels, generate calcium signals and communicate with immune cells and nerves around them.

One of those channels is transient receptor potential vanilloid 3, or TRPV3. It is prominent in keratinocytes, responds to warmth and several chemical activators, and has been linked to itch, pain and inflammatory signalling. That made it a plausible route for azelaic-acid stinging. Plausibility, though, is where many novel mechanisms have enjoyed an undeservedly long career.

Azelaic Acid May Turn Up the Gain

In 2026, Diwas Rawal, Wook-Joo Lee and Won-Sik Shim tested azelaic acid against a panel of candidate sensory receptors and channels. Their first result was negative and important: azelaic acid didn’t directly activate TRPV3, or the other candidates they tested. It did something more conditional.

When TRPV3 had already been stimulated, azelaic acid amplified the calcium response. The effect appeared in engineered cells, primary mouse keratinocytes and human HaCaT keratinocytes, a laboratory-grown human cell line. A TRPV3 antagonist reduced or abolished it. In mice, azelaic acid increased scratching when it was combined with a TRPV3 activator; repeated intradermal exposure to azelaic acid alone increased TRPV3 expression, scratching and mild skin lesions.

The researchers also used farnesyl pyrophosphate, or FPP, an activator made within our own biology rather than invented solely for the experiment. Azelaic acid amplified that response too.

The most faithful translation is closer to a volume control than a pain button. Azelaic acid may turn up the gain on a system already receiving input. An ingredient can dampen inflammatory pathways over weeks and still amplify an immediate sensory signal during application. The skin isn’t obliged to make those effects feel consistent to you.

The study also sets its own limits. It didn’t apply commercial products to human faces. The human evidence came from cultured keratinocytes, while much of the whole-animal work used injections into mouse skin rather than topical application. TRPV3 is now a strong candidate mechanism, not yet the sole explanation for every sting from every formula.

The work was conducted at Gachon University with support reported from South Korean public research programmes. Lacking the typical commercial skincare ties is helpful. It doesn’t turn a mouse injection into a human skincare trial.

Where the Barrier Gets a Vote

Barrier condition changes the setting in which the sensory signal is generated. I feel this in my own routine. Twenty per cent azelaic acid, in about as stripped-back a routine as you can build, and the sting still ranges from thirty seconds to ten minutes depending on the day. Nothing about the routine changed. Something about my day did.

The UK information for Finacea 15% gel states that azelaic acid penetrates damaged skin faster than intact skin. That fits barrier biology: a more permeable stratum corneum can allow applied chemicals to reach living epidermal tissue more readily. Inflammation can also lower the threshold at which chemical or thermal input becomes uncomfortable.

A barrier already contending with a retinoid, exfoliating acid, harsh cleanser, recent procedure or active dermatitis may therefore feel the same product more intensely. That is amplification, not proof of one cause. Azelaic acid can sting on relatively settled skin, and damaged skin can fail to sting at all.

Zoe Diana Draelos tested the relationship in 40 women with mild to moderate rosacea. At baseline, 62.5% responded to a lactic-acid sting test, yet that response didn’t predict who would sting with azelaic acid 15% gel. After two weeks, the study found no evidence of barrier damage in its TEWL or corneometry readings.

It was a small, short study of one commercial gel, and those instruments measure selected outputs rather than every structure or inflammatory process in the barrier. The fair conclusion is narrower: stinging wasn’t explained by the baseline sting test, and barrier damage wasn’t detected by the measurements used. If the sensation were a clean barrier test, the relationships should have paired off better. They didn’t.

The Sting Is on a Different Schedule

Does the sting mean azelaic acid is working? No, however tempting the reassurance.

The therapeutic effects in acne and rosacea develop through antimicrobial, anti-keratinising and inflammation-modulating actions over a longer timescale. In normal human keratinocytes, Arianna Mastrofrancesco and colleagues found that azelaic acid could reduce an experimentally induced inflammatory response through PPARγ, a receptor involved in suppressing inflammatory gene activity. An immediate sensory signal is not a biomarker for that process.

A product can work without stinging. It can sting and later work. It can also sting and remain a poor fit for the person using it. The sensation doesn’t sort those outcomes for you.

This is where ‘push through it’ becomes poor biology. Mild, brief tingling may be compatible with continued use under the product instructions. More pain means a louder sensory output; it doesn’t mean faster therapeutic progress. Tolerability isn’t a test of commitment.

Your Skin Still Gets a Veto

Mild tingling or warmth that appears after application and fades, without progressive redness or surface change, fits the recognised early tolerability pattern in the product information. That doesn’t make it beneficial. It means the sensation alone doesn’t demonstrate injury.

Persistent or escalating burning, marked redness, dryness, peeling, swelling or a developing rash carries different information. If your product was prescribed, its leaflet and your prescriber’s advice outrank a general article on the internet, including this one.

Hives, facial or eye swelling, wheezing or breathing difficulty sit in another category. They can indicate hypersensitivity and call for the product to be stopped and urgent medical assessment.

The better split isn’t sting versus no sting. It is brief and settling versus persistent, escalating or joined by visible inflammatory change.

The Answer

Azelaic acid stings because a formulation delivers the molecule into a sensory-active epidermis. The vehicle helps determine how much becomes available. Barrier condition and inflammation alter access and threshold. The best current mechanistic evidence suggests that azelaic acid can amplify TRPV3 signalling that is already active, rather than switching the channel on from nothing.

That is why the same ingredient can feel unremarkable on one day, sharp on another and quite different in another formula. It’s also why the sensation cannot diagnose your barrier or confirm efficacy.

Azelaic acid can calm inflammation over weeks and sting within minutes. The skin is allowed more than one verb.

Sensation is an output. Context gives it meaning.

References

Rawal, D., Lee, W.J. and Shim, W.S. (2026). Azelaic acid potentiates TRPV3 activity as a mechanism for skin irritation. Journal of Investigative Dermatology, 146(6), pp. 1693-1697.e6. https://doi.org/10.1016/j.jid.2026.01.022

Li, N., Wu, X., Jia, W., et al. (2012). Effect of ionization and vehicle on skin absorption and penetration of azelaic acid. Drug Development and Industrial Pharmacy, 38(8), pp. 985-994. https://doi.org/10.3109/03639045.2011.635376

Draelos, Z.D. (2004). Noxious sensory perceptions in patients with mild to moderate rosacea treated with azelaic acid 15% gel. Cutis, 74(4), pp. 257-260. https://pubmed.ncbi.nlm.nih.gov/15551720/

Mastrofrancesco, A., Ottaviani, M., Aspite, N., et al. (2010). Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARγ activation. Experimental Dermatology, 19(9), pp. 813-820. https://doi.org/10.1111/j.1600-0625.2010.01107.x

LEO Laboratories Limited. (2023). Finacea 15% Gel: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/240/smpc

US Food and Drug Administration. (2020). Finacea Gel 15%: Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021470s015s016lbl.pdf Gachon University. (2026). Gachon University research team identifies how azelaic acid can provoke skin irritation and itch. [Korean]. https://www.gachon.ac.kr/bbs/pharmacy/1042/118125/artclView.do

This article contains no affiliate links, sponsored content or product recommendations. Scientific claims are grounded in the peer-reviewed literature and official product information cited above. The US and UK tolerability figures come from regulatory documents for Finacea, a branded 15% gel. They are appropriate evidence for that formulation, not independent estimates for every azelaic-acid product. The 2010 PPARγ paper included Klaus Graupe, then a senior medical adviser at Intendis, the Bayer dermatology company responsible for Finacea at the time. The 2026 TRPV3 study was conducted at Gachon University and reported support from South Korean public research programmes; no commercial funder was identified. Commercial involvement doesn’t void a result, but it does make the exact product, comparator and endpoint especially important when deciding how far a conclusion can travel.